In an Alzheimer’s disease mouse model, liraglutide suppresses microglial activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, thereby reducing pro-inflammatory cytokine production and Aβ plaque burden [56]. The gene discussed is NLRP3; the disease is early-onset autosomal dominant Alzheimer disease.